PITTSBURGH, April 28, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE), a preclinical-stage biotechnology company focused on developing next generation therapies to treat rare genetic diseases caused by mutant genes, announced today the pricing of an underwritten public offering of 5,250,000 shares of its common stock, at a price to the public of $6.00 per share. The gross proceeds to NeuBase from the offering, before deducting the underwriting discounts and commissions and o
April 28, 2020
· 5 min read